AstraZeneca to Slash Costs by £1 Billion to Boost Drug Pipeline

By the Editorial Team · Saturday, October 31, 2026

AstraZeneca announced a three-year restructuring plan aiming to cut costs by £1.1 billion annually to accelerate investment in its drug development pipeline. This move supports the company's strategy to boost innovation and revenue growth as it targets £58.8 billion in annual sales by 2030.

AstraZeneca announced a major restructuring plan intended to reduce costs by approximately £1.1 billion annually, aiming to accelerate investment in its drug development pipeline. The three-year initiative is expected to incur up to £1.5 billion in restructuring charges, although the company has not disclosed specific details regarding the sources of these savings or the potential impact on its workforce.

The Cambridge-based pharmaceutical company reported stronger-than-expected financial results for the third quarter, with pre-tax profits rising 22% to £2.9 billion. This performance underscores AstraZeneca’s ongoing efforts to expand its portfolio and increase revenue.

Currently, the company has over 180 drug development projects underway as part of its strategic push to enhance innovation. AstraZeneca’s goal is to achieve annual sales of £58.8 billion by 2030, a target that CEO Pascal Soriot affirmed remains on track.

The restructuring plan represents a significant shift toward streamlining operations and reallocating resources to support the company’s long-term growth ambitions in a highly competitive sector.

This article was reported by synthesizing coverage from multiple independent news outlets to present a balanced, unbiased account. Read about our editorial standards. Spotted an error? Let us know.